Are you Dr. Bajaj?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 26 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9500 Euclid Ave # A-53
Cleveland, OH 44195Phone+1 216-445-0682Fax+1 216-445-1656- Is this information wrong?
Summary
- Dr. Harpreet Bajaj, MD is an endocrinologist in Cleveland, Ohio.
Education & Training
Hennepin HealthcareResidency, Internal Medicine, 2004 - 2007
Maulana Azad Medical CollegeClass of 2001
Clinical Trials
- Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria Start of enrollment: 2013 Oct 01
- Randomized Trial Comparing Colesevelam vs. Ezetimibe Start of enrollment: 2016 Jan 11
- The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians Start of enrollment: 2018 Oct 02
Publications & Presentations
PubMed
- 2 citationsImpact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLU...Thomas R. Pieber, Harpreet S. Bajaj, Simon Heller, Ting Jia, Kamlesh Khunti, David C. Klonoff, Steen Ladelund, Lawrence A. Leiter, Lily Wagner, Athena Philis-Tsimikas> ;Diabetes, Obesity & Metabolism. 2021 Oct 17
- 57 citationsEfficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.Juan P. Frias, Pernille Auerbach, Harpreet S. Bajaj, Yasushi Fukushima, Ildiko Lingvay, Stanislava Macura, Anette L. Søndergaard, Tsvetalina Tankova, Nikolaos Tentolou...> ;The Lancet. Diabetes & Endocrinology. 2021 Sep 1
- 41 citationsEfficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD TrialFrederik Persson, Peter Rossing, Priya Vart, Glenn M. Chertow, Fan Fan Hou, Niels Jongs, John J.V. McMurray, Ricardo Correa-Rotter, Harpreet S. Bajaj, Bergur V. Stefán...> ;Diabetes Care. 2021 Jun 28
- Join now to see all
Press Mentions
Novo Nordisk Tees up Phase 3 Trial for Once-Weekly InsulinSeptember 24th, 2020- Switching to Investigational Once-Weekly Insulin Icodec from Other Basal Insulins Demonstrated to Be Efficacious and Well-Tolerated for People with Type 2 Diabetes in Phase 2 TrialSeptember 22nd, 2020
Type 2 Diabetes May Be Preventable, but Why Isn't Type 1?November 14th, 2019- Join now to see all
